TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

CML

204 clinical trials

113 active
/
204 total (since 2015)
41
Phase 1 Active
78 total
75
Phase 2 Active
126 total
9
Phase 3 Active
18 total
3
Phase 4 Active
6 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Novartis 8 6 1
Shenzhen TargetRx, Inc. 3 2 0
Jiangsu Hansoh Pharmaceutical Co., Ltd. 3 0 0
Ascentage Pharma Group Inc. 2 3 0
Enliven Therapeutics 2 0 0
Il-Yang Pharm. Co., Ltd. 2 0 0
Ossium Health, Inc. 1 0 0
MacroGenics 1 0 0
Terns, Inc. 1 0 0
Incyte Biosciences International Sàrl 1 0 0
Orca Biosystems, Inc. 1 0 0
Otsuka Beijing Research Institute 1 0 0
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 1 0 0
Sun Pharma Advanced Research Company Limited 1 0 0
Kartos Therapeutics, Inc. 1 0 0
NCT04948333 ACTIVE NOT RECRUITING
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis Pharmaceuticals n=199
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT05456191 ACTIVE NOT RECRUITING
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Novartis Pharmaceuticals n=568
NCT04971226 ACTIVE NOT RECRUITING
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis Pharmaceuticals n=406
NCT06423911 RECRUITING
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Ascentage Pharma Group Inc. n=285
NCT05413915 ACTIVE NOT RECRUITING
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sarit Assouline n=164
NCT03459534 RECRUITING
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd. n=173
NCT03722420 ACTIVE NOT RECRUITING
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Il-Yang Pharm. Co., Ltd. n=238
NCT05753384 RECRUITING
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Poitiers University Hospital n=140
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04666259 COMPLETED
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Novartis Pharmaceuticals n=56
NCT03106779 COMPLETED
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis Pharmaceuticals n=233
NCT03746054 TERMINATED
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality
University Hospital, Angers n=80
NCT03959241 COMPLETED
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Medical College of Wisconsin n=431
NCT03117816 COMPLETED
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
Philipps University Marburg n=214
NCT02627677 TERMINATED
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
Ariad Pharmaceuticals n=44
NCT02115386 TERMINATED
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Novartis Pharmaceuticals n=7
NCT03079505 TERMINATED
Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Hamad Medical Corporation n=10

Data: ClinicalTrials.gov